keyword
MENU ▼
Read by QxMD icon Read
search

Iron sucrose esrd

keyword
https://www.readbyqxmd.com/read/28371203/the-available-intravenous-iron-formulations-history-efficacy-and-toxicology
#1
REVIEW
Michael Auerbach, Iain Macdougall
A number of intravenous iron formulations have been developed over the past 65 years which rely on dextran or other compounds to prevent uncontrolled release of free iron to the circulation. High molecular weight dextran was associated with a number of serious adverse reactions and was removed from markets worldwide in 2009. The preponderance of published evidence suggests that the formulations of parenteral iron currently available in the United States, including low molecular weight iron dextran, are all safe and effective and there are no major, clinically important differences among them in terms of either efficacy or safety...
June 2017: Hemodialysis International
https://www.readbyqxmd.com/read/27107522/sleep-disorders-in-esrd-patients-undergoing-hemodialysis
#2
Mohammad Reza Abassi, Amin Safavi, Masoumeh Haghverdi, Babak Saedi
Kidney failure affects different aspects of normal life. Among different manifestations, sleep problem can be considered as a common complaint of ESRD (End Stage Renal Disease) patients. In this study, we aimed to investigate the interrelationship between sleep disorders in ESRD patients and their characteristics. Through a cross-sectional study (2010-2011), 88 ESRD patients undergoing maintenance hemodialysis thrice weekly were recruited to enter the study. We used a self-administered questionnaire into which the data were reflected...
March 2016: Acta Medica Iranica
https://www.readbyqxmd.com/read/26361515/venous-versus-arterial-iron-administration-in-haemodialysis-influence-on-erythrocytes-antioxidant-parameters
#3
COMPARATIVE STUDY
C B Dogaru, C Capusa, L Gaman, E Torac, D Lixandru, M Gilca, L Iosif, C Muscurel, I Stoian, G Mircescu, V Atanasiu
Introduction Intravenous iron administration in patients treated by haemodialysis for end stage renal disease can exacerbate oxidative stress by increasing the level of free redox active iron. A way to reduce the impact of iron on oxidative stress in haemodialysis patients may be the administration of iron through arterial extracorporeal circuit. Objective The aim of our study was to compare the influence of iron route of administration (venous versus arterial extracorporeal circuit infusion) on antioxidant parameters in red blood cells of haemodialysis patients in order to clarify if arterial iron administration can have positive impacts related to iron induced oxidative stress...
2015: Journal of Medicine and Life
https://www.readbyqxmd.com/read/26311216/comparative-outcomes-of-predominant-facility-level-use-of-ferumoxytol-versus-other-intravenous-iron-formulations-in-incident-hemodialysis-patients
#4
COMPARATIVE STUDY
Medha Airy, Sreedhar Mandayam, Aya A Mitani, Tara I Chang, Victoria Y Ding, M Alan Brookhart, Benjamin A Goldstein, Wolfgang C Winkelmayer
BACKGROUND: Ferumoxytol was first approved for clinical use in 2009 solely based on data from trial comparisons with oral iron on biochemical anemia efficacy end points. To compare the rates of important patient outcomes (infection, cardiovascular events and death) between facilities predominantly using ferumoxytol versus iron sucrose (IS) or ferric gluconate (FG) in patients with end-stage renal disease (ESRD)-initiating hemodialysis (HD). METHODS: Using the United States Renal Data System, we identified all HD facilities that switched (almost) all patients from IS/FG to ferumoxytol (July 2009-December 2011)...
December 2015: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/24349622/at-pharmacologically-relevant-concentrations-intravenous-iron-preparations-cause-pancreatic-beta-cell-death
#5
Yuichi Masuda, Hirohito Ichii, Nosratola D Vaziri
BACK GROUND: Overt and subtle iron overload cause diabetes by lowering insulin production and promoting insulin resistance. Via divalent metal transporters pancreatic beta cells take up non-transferrin-bound iron which by catalyzing Fenton reaction can cause oxidative stress. Due to their strict dependence on mitochondrial glucose metabolism and limited antioxidant capacity, beta cells are exquisitely vulnerable to oxidative stress and hence catalytically active iron. Intravenous (IV) iron preparations are routinely used in the management of anemia in patients with end stage renal disease...
2013: American Journal of Translational Research
https://www.readbyqxmd.com/read/22722756/iron-sucrose-impairs-phagocytic-function-and-promotes-apoptosis-in-polymorphonuclear-leukocytes
#6
Hirohito Ichii, Yuichi Masuda, Tania Hassanzadeh, Mateen Saffarian, Sastry Gollapudi, Nosratola D Vaziri
BACKGROUND: With the recent implementation of bundling reimbursement policy, the use of intravenous (IV) iron preparations for the management of anemia in the end-stage renal disease (ESRD) population has dramatically increased. Iron overload increases the risk of infections in individuals with or without kidney disease. IV iron administration in ESRD patients impairs bacteriocidal capacity of polymorphonuclear leukocytes (PMNs) against Escherichia coli. These preparations consist of an elemental iron core and a carbohydrate shell...
2012: American Journal of Nephrology
https://www.readbyqxmd.com/read/22706571/effect-of-intravenous-vitamin-c-on-cytokine-activation-and-oxidative-stress-in-end-stage-renal-disease-patients-receiving-intravenous-iron-sucrose
#7
RANDOMIZED CONTROLLED TRIAL
Todd A Conner, Charles McQuade, Jonathan Olp, Amy Barton Pai
Reticuloendothelial blockade in hemodialysis patients prevents optimal intravenous (IV) iron utilization. Vitamin C has emerged as a potential therapy to improve anemia treatment by enhancing iron mobilization. However, Vitamin C can act as a pro-oxidant in the presence of iron. This was a prospective, open-label, crossover study. Thirteen patients with end-stage renal disease on hemodialysis and four healthy controls were assigned to receive 100 mg of IV iron sucrose (IS) or 100 mg of IV IS co-administered with 300 mg of IV Vitamin C (IS + C) in random sequence...
October 2012: Biometals: An International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine
https://www.readbyqxmd.com/read/22212390/iron-sucrose-promotes-endothelial-injury-and-dysfunction-and-monocyte-adhesion-infiltration
#8
Vaijinath S Kamanna, Shobha H Ganji, Stanislav Shelkovnikov, Keith Norris, Nosratola D Vaziri
BACKGROUND/AIMS: Intravenous (IV) iron preparations are widely used in the management of anemia in ESRD populations. Recent changes in reimbursement policy have dramatically increased the use of IV iron to lower the use of costly erythropoiesis-stimulating agents. These preparations are frequently administered with insufficient attention to the total body iron stores or presence of inflammation which is aggravated by excess iron. Endothelial injury and dysfunction are critical steps in atherosclerosis, thrombosis and cardiovascular disease...
2012: American Journal of Nephrology
https://www.readbyqxmd.com/read/21229380/non-transferrin-bound-iron-cytokine-activation-and-intracellular-reactive-oxygen-species-generation-in-hemodialysis-patients-receiving-intravenous-iron-dextran-or-iron-sucrose
#9
Amy Barton Pai, Todd Conner, Charles R McQuade, Jonathan Olp, Paul Hicks
Intravenous (IV) iron supplementation is widely used to support erythropoeisis in hemodialysis patients. IV iron products are associated with oxidative stress that has been measured principally by circulating biomarkers such as products of lipid peroxidation. The pro-oxidant effects of IV iron are presumed to be due at least in part, by free or non-transferrin bound iron (NTBI). However, the effects of IV iron on intracellular redox status and downstream effectors is not known. This prospective, crossover study compared cytokine activation, reactive oxygen species generation and oxidative stress after single IV doses of iron sucrose and iron dextran...
August 2011: Biometals: An International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine
https://www.readbyqxmd.com/read/17497463/is-there-a-difference-between-the-allergic-potencies-of-the-iron-sucrose-and-low-molecular-weight-iron-dextran
#10
RANDOMIZED CONTROLLED TRIAL
Tansu Sav, Bulent Tokgoz, Murat Hayri Sipahioglu, Murat Deveci, Ismail Sari, Oktay Oymak, Cengiz Utas
BACKGROUND: The objectives of the present trial were to compare the side effects and safety of two intravenous iron preparations (iron-dextran, iron-sucrose) in patients with end stage renal disease. METHODS: A total of 60 patients were randomized and assigned to one of two treatment groups (iron-dextran, n = 30; iron-sucrose, n = 30). A standard test dose of 25 mg of low molecular weight iron-dextran and iron-sucrose were administered over 15 minutes during the initial visit, monitoring very closely for adverse reactions...
2007: Renal Failure
https://www.readbyqxmd.com/read/16445566/effects-of-intravenous-abt-870-iron-iii-hydroxide-oligosaccharide-on-mean-arterial-pressure-and-heart-rate-in-the-anaesthetized-beagle-comparison-with-other-iron-containing-haematinic-agents
#11
COMPARATIVE STUDY
Lee C Preusser, Ryan M Fryer, Armin Gerhardt, Yanhui Hu, Leticia Delgado-Herrera, Joel Z Melnick, Laura A Williams, Bryan F Cox, Glenn A Reinhart
Iron-deficiency anaemia, a complication of end-stage renal disease (ESRD), is often treated with parenteral iron therapies that have been shown to produce dose-limiting hypotension in patients. ABT-870 (iron-(III)-hydroxide-oligosaccharide) is comprised of elemental iron complexed with oligosaccharide, a composition that we hypothesised would allow the hypotensive effects of parenteral iron therapy to be overcome, thus allowing a rapid rate of infusion to be well tolerated. Mean arterial pressure (MAP) and heart rate (HR) were monitored in anaesthetized dogs following the infusion of ABT-870 and iron sucrose administered at doses of 7...
December 2005: Clinical and Experimental Pharmacology & Physiology
https://www.readbyqxmd.com/read/16183420/trends-in-intravenous-iron-use-among-dialysis-patients-in-the-united-states-1994-2002
#12
Wendy L St Peter, Gregorio T Obrador, Tricia L Roberts, Allan J Collins
BACKGROUND: Two new intravenous (IV) iron products, ferric gluconate and iron sucrose, recently were approved for use in the United States. We report trends in IV iron use in both incident (1994 to 2001) and prevalent (1994 to 2002) Medicare US dialysis patients. METHODS: Included patients had Medicare as a primary payer. Recombinant human erythropoietin doses, IV iron use, and hemoglobin data were obtained from Medicare outpatient files. The most recent cohorts included 241,770 prevalent hemodialysis (HD) patients in 2002 and 11,744 incident HD patients in 2001...
October 2005: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/15365964/intravenous-iron-supplementation-in-children-on-hemodialysis
#13
Eveline Leijn, Leo A H Monnens, Elisabeth A M Cornelissen
BACKGROUND: Children with end-stage renal disease (ESRD) on hemodialysis (HD) are often absolute or functional iron deficient. There is little experience in treating these children with intravenous (i.v.) iron-sucrose. In this prospective study, different i.v. iron-sucrose doses were tested in children with ESRD on HD and the effect on iron status measured. METHODS: Fourteen patients were divided into three groups according to their actual iron status. Group A--iron deficient (ferritin (F)<100 microg/L, or F 100-400 microg/L and transferrin saturation (TSAT)<20%)...
May 2004: Journal of Nephrology
https://www.readbyqxmd.com/read/14979736/a-study-of-the-response-of-elderly-patients-with-end-stage-renal-disease-to-epoetin-alfa-or-beta
#14
Johann C B Nicholas
BACKGROUND: Anaemia correction in patients with end-stage renal disease has been enhanced following the use of epoetin alfa or beta and there are a number of studies detailing its application. Dialysis centres are dealing with greater numbers of elderly patients and anaemia correction in these individuals may differ by virtue of co-existing comorbidity and their age. OBJECTIVE: The aim of this study was to examine the response of the elderly patients to anaemia correction using a locally devised anaemia correction protocol while receiving dialysis...
2004: Drugs & Aging
https://www.readbyqxmd.com/read/14607997/intravenous-iron-as-adjuvant-therapy-a-two-edged-sword
#15
REVIEW
Ivor Cavill
The importance of iron in the manufacture of erythrocytes is self-evident. In recent years, the treatment of anaemia of end-stage renal disease with recombinant human erythropoietin (epoetin) has been optimized by adequate iron supply. Intravenous therapy with dextran-free iron compounds has become the ideal and necessary companion of epoetin therapy. Anxiety has been expressed by clinicians and researchers over the impact of excess levels of iron following i.v. administration. Their concerns have included the potential for short-term side effects such as anaphylactic reactions and response to 'free iron'...
November 2003: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/12846772/high-dose-parenteral-iron-sucrose-depresses-neutrophil-intracellular-killing-capacity
#16
RANDOMIZED CONTROLLED TRIAL
Robert Deicher, Farzad Ziai, Gerald Cohen, Marcus Müllner, Walter H Hörl
BACKGROUND: Iron is essential for the formation of hemoglobin. During long-term treatment with human recombinant erythropoietin (rhEPO), the majority of end-stage renal disease (ESRD) patients will not respond adequately to rhEPO unless substituted with intravenous iron. However, concern exists about possible detrimental effects of parenteral iron on cellular host defense and iron-mediated increments of oxidative stress. METHODS: We analyzed phagocytic functions of polymorphonuclear leukocytes (PMN) isolated from 20 ESRD patients on peritoneal dialysis in response to 300 mg of iron sucrose or placebo administered intravenously over two hours in a randomized, double-blind manner...
August 2003: Kidney International
https://www.readbyqxmd.com/read/12227686/impact-of-iron-dextran-on-polymorphonuclear-cell-function-among-hemodialysis-patients
#17
COMPARATIVE STUDY
D Guo, B L Jaber, S Lee, M C Perianayagam, A J King, B J G Pereira, V S Balakrishnan
BACKGROUND: Polymorphonuclear cell (PMN) dysfunction and the increased use of parenteral iron may be important contributory factors to bacterial infections among patients with end-stage renal disease (ESRD) on maintenance hemodialysis (HD). We compared the in vitro impact of a commonly used parenteral iron preparation, iron dextran, on PMN function and viability between a group of HD patients with normal iron indices and healthy subjects. METHODS: Eleven patients with ESRD on HD and 10 healthy subjects were studied...
August 2002: Clinical Nephrology
https://www.readbyqxmd.com/read/12091609/adjunctive-therapy-in-anaemia-management
#18
REVIEW
Walter H Hörl
Iron supplementation is essential for adequate response to recombinant human erythropoietin (rHuEPO) or darbepoetin alfa. Oral iron therapy is often ineffective as the quantity of iron absorbed after oral intake may be insufficient to keep pace with the demands of rHuEPO-stimulated erythropoiesis in patients with end-stage renal disease (ESRD). Currently available i.v. iron preparations include dextran, iron gluconate, and iron sucrose. As rare, but serious, adverse reactions to i.v. iron dextran have been reported, alternative preparations may be preferred...
2002: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/12087566/parenteral-iron-formulations-a-comparative-toxicologic-analysis-and-mechanisms-of-cell-injury
#19
COMPARATIVE STUDY
Richard A Zager, Ali C M Johnson, Sherry Y Hanson, Haimanot Wasse
BACKGROUND: Multiple parenteral iron (Fe) formulations exist for administration to patients with end-stage renal disease. Although there are concerns regarding their potential toxicities, no direct in vitro comparisons of these agents exist. Thus, the present study contrasted pro-oxidant and cytotoxic potentials of four available Fe preparations: Fe dextran (Fe dext), Fe sucrose (Fe sucr), Fe gluconate (Fe gluc), and Fe oligosaccharide (Fe OS). METHODS: Differing dosages (0...
July 2002: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/10776080/iron-management-innovative-solutions-to-persistent-challenges-focus-on-ferrlecit
#20
REVIEW
S Vogel, S Schweitzer, S Seiler
The use of sodium ferric gluconate in sucrose injection (Ferrlecit) in the treatment of anemia in patients with end stage renal disease (ESRD) was the major topic at the symposium "Iron Management: Innovative Solutions to Persistent Challenges," held April 14, 1999 during the annual ANNA 30th National Symposium in Baltimore, Maryland. Chairperson Susan Vogel, MHA, RN, CNN, addressed the challenges of anemia management and the limitations of oral iron supplements. She described available intravenous (i.v.) iron therapies and reviewed clinical trial data that demonstrated an excellent safety and efficacy profile for the newly approved i...
October 1999: ANNA Journal
keyword
keyword
160431
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"